A case of complete remission of intractable gestational choriocarcinoma with subsequent chemotherapy after pembrolizumab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A case of complete remission of intractable gestational choriocarcinoma with subsequent chemotherapy after pembrolizumab

Published:2023-09 Issue:5 Volume:62 Page:745-748
ISSN:1028-4559
Container-title:Taiwanese Journal of Obstetrics and Gynecology
language:en
Short-container-title:Taiwanese Journal of Obstetrics and Gynecology

Author:

Niimi Kaoru,Yamamoto Eiko,Oda Yukari,Nishiko Yuki,Shibata Mayu,Nishino Kimihiro,Kajiyama Hiroaki

Funder

Ministry of Education, Culture, Sports, Science and Technology

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology

Reference17 articles.

1. Epidemiologic study on gestational trophoblastic diseases in Japan;Yamamoto;Journal of gynecologic oncology,2022

2. Secondary chemotherapy for high-risk gestational trophoblastic neoplasia;Lurain;Gynecol Oncol,2005

3. A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia;Powles;Br J Cancer,2007

4. The efficacy and toxicity of 4-day chemotherapy with methotrexate, etoposide and actinomycin D in patients with choriocarcinoma and high-risk gestational trophoblastic neoplasia;Sato;Int J Clin Oncol,2020

5. An extrauterine extensively metastatic epithelioid trophoblastic tumor responsive to pembrolizumab;Bell;Gynecologic oncology reports,2021

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Corrigendum to “A case of complete remission of intractable gestational choriocarcinoma with subsequent chemotherapy after pembrolizumab” [Taiwan J Obst Gynecol 62 (5) (2023) 745–748];Taiwanese Journal of Obstetrics and Gynecology;2024-05

2. Front-line chemoimmunotherapy for treating epithelial ovarian cancer: Part II promising results of phase 2 study of paclitaxel-carboplatin-oregovomab regimen;Taiwanese Journal of Obstetrics and Gynecology;2024-01

3. Front-line chemo-immunotherapy for treating epithelial ovarian cancer: Part I CA125 and anti-CA125;Taiwanese Journal of Obstetrics and Gynecology;2023-11

4. Antineoplastics;Reactions Weekly;2023-09-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3